Section divider

Since the early 1990s, keeping families healthy and free from malaria.

  • From 2016 to 2018, more than 217,000 cases of malaria were confirmed by testing and then treated using artemisinin-based combination therapy, as recommended by the World Health Organization.
  • In this same time period, more than 165,000 pregnant women received intermittent preventive treatment for malaria under direct observation—thereby providing protection from the dangers of malaria in pregnancy
  • The percentage of deaths due to malaria in targeted district hospitals decreased by 17 percentage points, from 60% (in six district hospitals) in 2013 to 43% (in 10 district hospitals) in 2018.
  • The rates of intermittent preventive treatment of malaria during pregnancy increased from 2012 to 2018—from 37% to 86% for first-dose treatment and 28% to 61% for second-dose treatment.

Our Technical Areas in Chad

Our Work in Chad

Malaria is the leading cause of morbidity and mortality in Chad and Cameroon, and is particularly dangerous for children and pregnant women. With support from ExxonMobil, Jhpiego is strengthening the capacity of the Chadian and Cameroonian Ministries of Health, the National Malaria Control Programs, health care providers and community health volunteers to provide high-quality malaria prevention and treatment for nearly 1,180,000 people living in 10 malaria-endemic districts along ExxonMobil’s 1,070-kilometer pipeline. The nine districts are Doba, Bodo, Béboto, Bébédjia, Goré, Bessao, Laramanaye, Donia, Kara (in Chad), and Kribi (in Cameroon). In addition to leading the development of national-level malaria guidelines, training manuals and reference materials, Jhpiego has trained health care providers, supervisors and community health volunteers to provide health services and/or health messages. These interventions have resulted in provision of lifesaving treatment to people with confirmed cases of malaria and improved coverage for intermittent preventive treatment of malaria among pregnant women.